DossierENTITY

RayThera

Coverage of RayThera in the Nexus archive.

Earliest in view: Jun 18 · 13:40 UTCMost recent: Jun 18 · 13:40 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 18 · 13:40 UTCQUARTZ
Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
Biogen is acquiring RayThera for up to $1 billion, adding small-molecule anti-inflammatory drug candidates to its pipeline. The lead asset from RayThera is expected to begin human trials this summer.